Dabigatran Reversal with Idarucizumab.

Authors

Charles V. Pollack, Thomas Jefferson University, Philadelphia, PA, United StatesFollow
Paul A Reilly, Boehringer Ingelheim, Ridgefield, CT, United StatesFollow
Jeffrey I Weitz, McMaster University, Hamilton, ON, CanadaFollow

Document Type

Article

Publication Date

10-26-2017

Comments

This article has been peer reviewed. It was published in: New England Journal of Medicine.
Volume 377, Issue 17, 26 October 2017, Pages 1691-1692.
The published version is available at DOI: 10.1056/NEJMc1711337

Copyright © © 2017 Massachusetts Medical Society

Recommended Citation

Pollack, Charles V.; Reilly, Paul A; and Weitz, Jeffrey I, "Dabigatran Reversal with Idarucizumab." (2017). Department of Medicine Faculty Papers. Paper 223.
https://jdc.jefferson.edu/medfp/223

PubMed ID

29069562